Unknown

Dataset Information

0

Disulfiram bolsters T-cell anti-tumor immunity through direct activation of LCK-mediated TCR signaling


ABSTRACT: Activation of the T-cell antigen receptor (TCR)-CD3 complex is critical to induce the anti-tumor response of CD8+ T cells. Here, we found that disulfiram (DSF), an FDA-approved drug previously used to treat alcohol dependency, directly activates TCR signaling. Mechanistically, DSF covalently binds to Cys20/Cys23 residues of lymphocyte-specific protein tyrosine kinase (LCK) and enhances its Tyr394 phosphorylation, thereby promoting LCK kinase activity and boosting effector T cell function, interleukin-2 production, metabolic reprogramming, and proliferation. Furthermore, our in vivo data revealed that DSF promotes anti-tumor immunity against both melanoma and colon cancer in mice by activating CD8+ T cells, and this effect was enhanced by anti-PD-1 co-treatment. We conclude that DSF directly activates LCK-mediated TCR signaling to induce strong anti-tumor immunity, providing novel molecular insights into the therapeutic effect of DSF on cancer .

SUBMITTER: Prof. Feng Wang 

PROVIDER: S-SCDT-EMBOJ-2022-110636 | biostudies-other |

REPOSITORIES: biostudies-other

Similar Datasets

| S-EPMC8068026 | biostudies-literature
| S-EPMC3674773 | biostudies-literature
| S-EPMC6307194 | biostudies-literature
| S-EPMC9232393 | biostudies-literature
| S-EPMC6585057 | biostudies-literature
| S-EPMC9106921 | biostudies-literature
| S-EPMC7927154 | biostudies-literature
| S-EPMC5694758 | biostudies-literature
| S-EPMC5081367 | biostudies-literature
2021-07-27 | PXD027596 | Pride